An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 214028
Company: ABBVIE

Products on NDA 214028

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
VUITY	PILOCARPINE HYDROCHLORIDE	1.25%	SOLUTION/DROPS;OPHTHALMIC	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 214028

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
10/28/2021	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214028s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214028Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214028Orig1s000TOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
03/08/2023	SUPPL-3	Manufacturing (CMC)-Packaging	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214028Orig1s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/214028Orig1s003ltr.pdf
03/28/2023	SUPPL-2	Efficacy-New Dosing Regimen	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214028Orig1s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/214028Orig1s002ltr.pdf
08/16/2022	SUPPL-1	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214028s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/214028Orig1s001ltr.pdf

Labels for NDA 214028

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
03/28/2023	SUPPL-2	Efficacy-New Dosing Regimen	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214028Orig1s002lbl.pdf
03/08/2023	SUPPL-3	Manufacturing (CMC)-Packaging	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214028Orig1s003lbl.pdf
08/16/2022	SUPPL-1	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214028s001lbl.pdf
10/28/2021	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214028s000lbl.pdf

Therapeutic Equivalents for NDA 214028

VUITY

SOLUTION/DROPS;OPHTHALMIC; 1.25%
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
PILOCARPINE HYDROCHLORIDE	PILOCARPINE HYDROCHLORIDE	1.25%	SOLUTION/DROPS;OPHTHALMIC	Prescription	No	AB	217733	AMNEAL
VUITY	PILOCARPINE HYDROCHLORIDE	1.25%	SOLUTION/DROPS;OPHTHALMIC	Prescription	Yes	AB	214028	ABBVIE

Top